

◆ DRXT18s03 (iPS cells expressing the third highest HLA in Japan※1)

Clone ID	DRXT18s03	Product	Human iPS cells
Source	Peripheral Blood, Human	Race	Japanese
Passage No.	9	Gender	Male
Lot No.	20170708-08	Manufacture Dates	July 8 th , 2017
Culture medium	StemFit AK03N	Substrate	iMatrix-511MG
Culture Method	Feeder-free (**2)		
Plasmids for	pCE-hSK, pCE-hUL, pCE-hOCT3/4, pCE-mp53DD, pCXB-EBNA1		
reprograming			
Use and Provision	Please check our web site ;		
of this cell stock	https://www.cira-foundation.or.jp/e/project/stock.html		

^(%1) **Reference**; Okita, *et. al.*, Nat Methods. 2011 8(5): 409-412

Test Result

Test	Method	Result	
Sterility	BacT/ALERT	Negative	
Mycoplasma	PCR	Negative	
Endotoxin	LAL	≦ 5 EU/mL	
Virus			
(HBV, HCV, HIV, HTLV,	PCR	Negative	
Parvovirus B19)			
HLA typing	PCR-SBT	Consistent with the donor cells	
(HLA-A, B, DR)	FUR-301	Consistent with the donor cens	
STR genotyping	PCR	Consistent with the donor cells	
Morphology	Microscope	Consistent with human ES cells	
Karyotype	Conventional Giemsa analysis G-banding	46,XY[20]	
Plasmid remnants	qPCR	Below the limit of quantification	
CNV ^(*3)	WGS, SNP	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.83) and Shibata list ^(**5) .	
SNV/Indel ^(※4)	WGS, WES	No de novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.83) and Shibata list ^(※5) .	
Undifferentiated	Microarray ^(※7)	POU5F1: 5.3%、NANOG: 5.6% (Relative expression levels of GAPDH)	
markers	Flow cytometry (**7)	TRA-1-60: 92.7% SSEA4: 99.4% TRA-2-49: 99.4%	


^(%2) Reference; Nakagawa, et. al., Nat Biotechnol. 2008 26(1):101-106



Thawed postnatal cells	Counting the number of the cells (**6, 7)	1.45 × 10 ⁵ cells (Survival rate; 93.5%)
Number of proliferating cells after thawing	Counting the number of the cells after culturing for 6 days ^(%6, 7) .	7.1×10^5 cells (Number of seeded cells : 1.39 $\times 10^5$ cells)
Doubling time (h)	Counting the number of the cells (**6, 7)	P12→P13: 33.7 P13→P14: 43.6 P14→P15: 27.4 P15→P16: 33.7 P16→P17: 34.8

- (%3) CNV; Copy Number Variation
- (¾4) SNV/Indel; Single nucleotide variants /Insertion Deletion
- (%5) The PMDA Science Board "Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials" (Cellular- and Tissue-based Products Subcommittee, 20 August 2013)
- (※6) ThermoFisher Countess®
- (※7) The result of # 1 out of 3 frozen stocks is shown.

■Image



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)

